Theralase to Present Interim Clinical Data at Upcoming Urological Forums

Theralase® Technologies Inc., a clinical stage pharmaceutical company, has announced its plans to host advisory board meetings at the Canadian Urological Association Bladder Cancer Forum in Toronto, Ontario, and the American Urology Association meeting in San Antonio, Texas. These meetings aim to present the Phase II interim clinical data of its Study II and discuss patient enrollment strategies.

Study II focuses on evaluating the effectiveness of Theralase's Photo Dynamic Compounds (PDCs) in treating Bacillus Calmette-Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ (NMIBC CIS). The technology offers a promising alternative to bladder removal surgery, showcasing significant clinical advantages in safety and efficacy through the use of Ruvidar™-based photodynamic therapy.

Arkady Mandel MD, Ph.D., DSc, the company's Chief Scientific Officer, has expressed optimism regarding the potential of this technology to provide a novel, effective treatment option for patients with limited alternatives. Theralase aims to complete patient recruitment for the Phase II study by the end of the year, moving closer to commercializing its breakthrough therapy for bladder cancer.